Genotype-tailored Treatment of Symptomatic Acid-Reflux in Children With Uncontrolled Asthma

PHASE3CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

October 31, 2017

Primary Completion Date

January 18, 2024

Study Completion Date

January 18, 2024

Conditions
AsthmaGastroesophageal Reflux
Interventions
DRUG

commercially available lansoprazole

these participants will receive a one-time dose of lansoprazole followed by PK analysis and then once daily lansoprazole for 24 weeks

DRUG

matched placebo

these participants will receive a one-time dose of lansoprazole followed by PK analysis and then once daily placebo for 24 weeks

Trial Locations (2)

27710

Duke University Medical Center, Durham

32207

Nemours Children's Specialty Care, Jacksonville

All Listed Sponsors
collaborator

Thrasher Research Fund

OTHER

collaborator

Nemours Children's Clinic

OTHER

lead

Jason Lang, M.D., M.P.H.

OTHER

NCT03015610 - Genotype-tailored Treatment of Symptomatic Acid-Reflux in Children With Uncontrolled Asthma | Biotech Hunter | Biotech Hunter